Stoke Therapeutics, Inc. Income Statement
STOK / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Stoke Therapeutics, Inc. reported $184M in revenue and $7M in net loss for FY2025. Revenue has grown at a 145.9% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $184.4M | $36.6M | $8.8M | $12.4M | - | - | - | - |
| SG&A Expense | $67.1M | $48.8M | $41.3M | $31.9M | $31.9M | $20.8M | $11.9M | $4.4M |
| R&D Expense | $137.9M | $89.1M | $82.2M | $54.2M | $54.2M | $32.2M | $23.8M | $8.4M |
| Operating Income | -$20.6M | -$101.4M | -$114.8M | -$86.1M | -$86.1M | -$53.0M | -$35.7M | -$12.8M |
| Interest Expense | $9.0K | $26.0K | $49.0K | - | - | - | - | - |
| Income Tax | $0 | - | - | - | - | - | - | - |
| Net Income | -$6.9M | -$89.0M | -$104.7M | -$85.8M | -$85.8M | -$52.2M | -$32.3M | -$12.5M |
| EPS (Basic) | -$0.12 | -$1.65 | -$2.38 | -$2.34 | -$2.34 | - | - | - |
| EPS (Diluted) | -$0.12 | -$1.65 | -$2.38 | -$2.34 | -$2.34 | - | - | - |
| Shares Outstanding | 58.9M | 54.0M | 45.9M | 36.9M | 36.7M | 33.5M | 18.0M | 709.3K |
| Operating Margin | -11.2% | -277.3% | -1307.2% | -693.8% | - | - | - | - |
| Profit Margin | -3.7% | -243.4% | -1192.5% | -691.7% | - | - | - | - |